{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022600","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-05-13T11:05:34+00:00","discovered_at":"2026-05-13T11:10:00.319675+00:00","generated_at":"2026-05-13T11:12:40.666998+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xtant Medical Q1 2026 net loss $3.1M; revenue falls to $20.9M, raises 2026 guidance to $101-105M","bullets":["Q1 2026 revenue $20.9M vs $32.9M YoY; decline driven by asset sale to Companion Spine and license revenue ceasing.","Net loss of $3.1M vs net income of $58K in Q1 2025; non-GAAP adjusted EBITDA loss $1.6M vs +$3.0M.","Full-year 2026 revenue guidance raised to $101-105M from $95-99M reflecting HEMOBLAST incremental revenue.","Entered exclusive US distribution for Dilon Technologies' HEMOBLAST Bellows; hired approx. 20-person sales team.","Reduced total indebtedness by $13.3M; cash $12.2M, availability under revolver $11.8M as of March 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022600","json":"https://secwatch.observer/filing/0001493152-26-022600.json","markdown":"https://secwatch.observer/filing/0001493152-26-022600.md","text":"https://secwatch.observer/filing/0001493152-26-022600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/0001493152-26-022600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:12:40.666998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ffbe1253535dbc9f8d6cdb80453219d56a57747","claim":"Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $20.9 million, net income net loss was $3.1 million. Guidance raised.","evidence_excerpt":"conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights ● Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/0001493152-26-022600-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$20.9 million"},{"label":"Net income","value":"net loss was $3.1 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}